Ask AI

EU Expert Think Tank: Global Perspectives and Clinical Resources to Optimize Antibody–Drug Conjugate Therapies in Metastatic HR-Positive/HER2-Negative or TNBC 

Video
This activity is available for 0.25 CME/CE credit(s).

Released: August 13, 2026

Expiration: February 12, 2027

See Activity Collection

Increase your confidence in the use of antibody–drug conjugates for patients with HR-positive/HER2-negative or triple-negative metastatic breast cancer by reviewing the latest clinical trial data, current treatment guidelines, and toxicity management through certified micro-text modules, downloadable slides, and a ClinicalThought expert commentary.

ADCs in HR Pos HER2 Neg or TNBC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with breast cancer do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Based on the emerging clinical data from the phase III ASCENT-03 trial, which efficacy outcome supported first-line use of sacituzumab govitecan-hziy in patients with advanced TNBC who were not candidates for PD-1/PD-L1 inhibitor therapy?

4.

A 60-year-old woman has HR-positive/HER2-negative metastatic breast cancer that progressed after endocrine therapy with a CDK4/6 inhibitor. She subsequently received 2 lines of systemic chemotherapy for metastatic disease. She has no history of interstitial lung disease and wishes to continue active treatment.

Which of the following is an EMA-approved anti–TROP-2 ADC that would be most appropriate for this patient?